James Liebmann to Humans
This is a "connection" page, showing publications James Liebmann has written about Humans.
Connection Strength
0.039
-
Salhab M, Migdady Y, Donahue M, Xiong Y, Dresser K, Walsh W, Chen BJ, Liebmann J. Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. J Immunother Cancer. 2018 05 29; 6(1):42.
Score: 0.023
-
Galera P, Haynes S, Sulmasy P, Bailey JA, Greene M, Vauthrin M, Brettler D, Liebmann J, Mark Madison J, Weinstein R. Physiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia. J Clin Apher. 2016 Aug; 31(4):393-7.
Score: 0.005
-
Lui JK, Ogunsua AA, Hatch SC, Liebmann J, Scully G. The diagnostic utility of tumor markers: a teachable moment. Am J Med. 2015 May; 128(5):e9-10.
Score: 0.005
-
Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, Kuepfer C, Singer JW, Fayad LE. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer. 2011 Nov 15; 117(22):5067-73.
Score: 0.004
-
Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007 Aug; 30(4):350-7.
Score: 0.003